Physical activity
OtherPhysical activity will carry out 3 times per week during 12 weeks for intervention arm
NCT Number: NCT02057783
Investigators hypothesize that CPAP treatment for suppressing OSAS in combination with a physical activity program will optimize 24-hour blood pressure control in patients with OSA-related resistant hypertension.
Interested in participating?
Request Info18 year–80 year
All sexes
Interventional
Not applicable
Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ), Québec, Canada
HIPARCO Study, the largest Randomized Clinical Trial (RCT) in the field (n=194) recently published in JAMA (9 December 2013) also showed a significant but limited impact of CPAP on blood pressure. In an Intention To Treat analysis, CPAP significantly improved 24-h mean BP (3.0 mmHg; 95% CI 0.3 to 5.8; p=0.031) and DBP (3.2 mmHg; 95% CI 1.0 to 5.4; p=0.005) but not SBP (3.1; 95% CI -0.6 to 6.7; p=0.098). Moreover, patients in the CPAP group had 2.4 (1.2-5.1; p=0.019) times greater probability of recovering their dipper pattern. As CPAP alone is not enough in OSAS to sufficiently improve BP, further studies should address the efficacy of combined therapies in OSAS patients with resistant hypertension.
Investigators hypothesize that CPAP treatment for suppressing OSAS in combination with a physical activity program will optimize 24-hour blood pressure control in patients with OSA-related resistant hypertension.
Originality: Up to now no study has assessed the effects of combining physical activity with CPAP treatment in patients with sleep apnea and resistant hypertension. Our work is will be the first aiming at evaluating the benefit of this combination on the control of the systolic blood arterial pressure.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Physical activity will carry out 3 times per week during 12 weeks for intervention arm
Time frame: To baseline at 12 weeks
Systolic arterial blood pressure assessed by 24-hours home blood pressure monitoring
Time frame: To baseline at 12 weeks
diastolic arterial blood pressure assessed by 24-hours home blood pressure monitoring
Time frame: To baseline at 12 weeks
Mean arterial blood pressure assessed by 24-hours home blood pressure monitoring
Time frame: To baseline at 12 weeks
Change in physical activity: number of hour per day of physical activity
Time frame: To baseline at 12 weeks
pulse wave velocity
Time frame: To baseline at 12 weeks
Change in physical activity : Metabolic Equivalents (METS)
Time frame: To baseline at 12 weeks
Change in physical activity : Number of steps per day
Time frame: To baseline at 12 weeks
Change in sleep duration: Sleep to lying position duration ratio
Contact information is provided by the study sponsor or research team.
AGIR à Dom
Other
Comparison of Standard Treatment by Continuous Positive Airway Pressure (CPAP) and CPAP Combined to a Physical Activity Program for Reducing Blood Pressure in Sleep Apnea Patients With Resistant Hypertension: RAP Randomized Controlled Trial
Acronym: RAP
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06246396
Hypertension Resistant to Conventional Therapy, Hypertension, Resistant to Conventional Therapy
Gainesville, Florida, United States
View Trial DetailsNCT06518915
Hypertension Resistant to Conventional Therapy, Hypertension, Resistant to Conventional Therapy
Münster, North Rhine-Westphalia, Germany
View Trial DetailsNCT05017935
Cardiovascular Diseases, Essential Hypertension
Chula Vista, California, United States
View Trial DetailsNCT05395403
Cardiovascular Diseases, Hypertension
Birmingham, Alabama, United States
View Trial Details